Caspofungin therapy of neonates with invasive candidiasis

被引:141
作者
Odio, CM
Araya, R
Pinto, LE
Castro, CE
Vasquez, S
Alfaro, B
Sàenz, A
Herrera, ML
Walsh, TJ
机构
[1] Sch Med Sci, San Jose, Costa Rica
[2] Natl Canc Inst, Pediat Oncol Branch, Bethesda, MD USA
[3] Hosp Nacl Ninos Dr Carlos Saenz Herrera, Div Infect Dis & Neonatol, San Jose, Costa Rica
关键词
caspofungin; amphotericin B; neonatal; candidiasis; candidemia; endocarditis; meningitis; neonatal intensive care unit; prematures;
D O I
10.1097/01.inf.0000145408.51526.0a
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Invasive candidiasis is an increasing problem in neonatal intensive care units worldwide and is an important cause of morbidity, mortality and prolongation of hospital stay. Despite administration of amphotericin B, invasive candidiasis in neonates is sometimes complicated by persistent fungemia and refractory invasive candidiasis. The problem has been augmented by the increasing prevalence of non-albicans species that often are resistant to fluconazole and to amphotericin B. Population and Methods: The population consisted of 1 term and 9 premature neonates with invasive candidiasis caused by Candida albicans (n = 4), Candida parapsilosis (n = 3), Candida tropicalis (n = 2) and Candida glabrata (n = 1). Despite initial therapy with deoxycholate amphotericin B, blood cultures remained positive in all patients for 13-49 days. Invasive candidiasis progressed to meningitis and enlarging renal Candida bezoars in the kidney of one patient and an enlarging atrial vegetation in another. Another patient developed severe hypokalemia refractory to potassium supplementation. Two of the C. albicans and all of the non-albicans Candida isolates were resistant to fluconazole; the C. glabrata isolate was resistant to amphotericin B. Amphotericin B was discontinued and caspofungin initiated in all patients in a dosage of 1 mg/kg/d for 2 days followed by 2 mg/kg/d. Results: All positive blood cultures cleared between 3 and 7 days after initiation of caspofungin, the atrial vegetation resolved and the renal Candida bezoars disappeared. Renal and hepatic function tests did not show any values above normal throughout caspofungin therapy. There were no attributable clinical adverse events during the administration of caspofungin in any of the patients. Conclusions: Caspofungin was effective, safe and well-tolerated as an alternative therapy for persistent and progressive candidiasis in those neonates who were unresponsive to or intolerant of deoxycholate amphotericin B.
引用
收藏
页码:1093 / 1097
页数:5
相关论文
共 35 条
  • [1] Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice
    Abruzzo, GK
    Gill, CJ
    Flattery, AM
    Kong, L
    Leighton, C
    Smith, JG
    Pikounis, VB
    Bartizal, K
    Rosen, H
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) : 2310 - 2318
  • [2] Evaluation of the echinocandin antifungal MK-0991 (L-743,872): Efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis
    Abruzzo, GK
    Flattery, AM
    Gill, CJ
    Kong, L
    Smith, JG
    Pikounis, VB
    Balkovec, JM
    Bouffard, AF
    Dropinski, JF
    Rosen, H
    Kropp, H
    Bartizal, K
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) : 2333 - 2338
  • [3] Management of invasive candidal infections: Results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature
    Anaissie, EJ
    Darouiche, RO
    AbiSaid, D
    Uzun, O
    Mera, J
    Gentry, LO
    Williams, T
    Kontoyiannis, DP
    Karl, CL
    Bodey, GP
    [J]. CLINICAL INFECTIOUS DISEASES, 1996, 23 (05) : 964 - 972
  • [4] Randomized, double-blind, Multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases
    Arathoon, EG
    Gotuzzo, E
    Noriega, LM
    Berman, RS
    DiNubile, MJ
    Sable, CA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (02) : 451 - 457
  • [5] BALEY JE, 1984, PEDIATRICS, V73, P153
  • [6] In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
    Bartizal, K
    Gill, CJ
    Abruzzo, GK
    Flattery, AM
    Kong, L
    Scott, PM
    Smith, JG
    Leighton, CE
    Bouffard, A
    Dropinski, JF
    Balkovec, J
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) : 2326 - 2332
  • [7] Neonatal candidemia and end-organ damage: A critical appraisal of the literature using meta-analytic techniques
    Benjamin, DK
    Poole, C
    Steinbach, WJ
    Rowen, JL
    Walsh, TJ
    [J]. PEDIATRICS, 2003, 112 (03) : 634 - 640
  • [8] BUTLER KM, 1988, PEDIATR CLIN N AM, V35, P543
  • [9] Persistently positive cultures and outcome in invasive neonatal candidiasis
    Chapman, RL
    Faix, RG
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (09) : 822 - 827
  • [10] CANDIDEMIA IN CHILDREN WITH CENTRAL VENOUS CATHETERS - ROLE OF CATHETER REMOVAL AND AMPHOTERICIN-B THERAPY
    DATO, VM
    DAJANI, AS
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1990, 9 (05) : 309 - 314